Dr Michael Ohh
Bernard and Francine Dorval Prize co-recipient in 2010
Dr Ohh is an associate professor in the department of laboratory medicine and pathobiology at the University of Toronto. He is known for his paradigm-shifting work in the field of oxygen-sensing pathways in cancer development and progression. His work of deciphering these pathways at cellular and molecular levels has led to innovations in novel anti-cancer therapies. His laboratory is also an excellent training ground for graduate students, postdoctoral fellows and clinician-scientists interested in basic cancer biology and translational research.
Dr Ohh received his PhD from the University of British Columbia in 1995 and was a Medical Research Council (CIHR) and National Cancer Institute of Canada postdoctoral fellow at the Dana-Farber Cancer Institute at Harvard Medical School prior to joining University of Toronto. He holds a Canada Research Chair in Molecular Oncology.
Dr Ohh has published over 50 peer-reviewed papers in high-impact journals such as Nature Medicine and Science with over 5,000 combined citations. He is frequently invited to present his concept-provoking ideas and findings at both basic research and clinical meetings in Canada, the United States and Europe. combined citations. He is frequently invited to present his concept-provoking ideas and findings at both basic research and clinical meetings in Canada, the United States and Europe.
Great progress has been made
Some cancers, such as thyroid and testicular, have survival rates of over 90%. Other cancers, such as pancreatic, brain and esophageal, continue to have very low survival rates.